Advanced in Pseudomonas Stutzeri Infections

Dr. Raksha Jain

Pulmonary Medicine
University Of Texas Southwestern Medical Center At Dallas
5323 Harry Hines Blvd, 
Dallas, TX 
Advanced in Pseudomonas Stutzeri Infections
University Of Texas Southwestern Medical Center At Dallas
5323 Harry Hines Blvd, 
Dallas, TX 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Raksha Jain is a Pulmonary Medicine provider in Dallas, Texas. Dr. Jain is rated as an Advanced provider by MediFind in the treatment of Pseudomonas Stutzeri Infections. Her top areas of expertise are Cystic Fibrosis, Secondary Immunodeficiency (SID), Newborn Jaundice, Bronchiectasis, and Lung Transplant.

Her clinical research consists of co-authoring 105 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 7 articles and participated in 1 clinical trial in the study of Pseudomonas Stutzeri Infections.

Specialties
Pulmonary Medicine
Licenses
Internal Medicine in MO
Hospital Affiliations
UT Of Texas Southwestern University Hospital - William P. Clements Jr.
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Baylor Scott & White Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Community First Health Plans
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Superior Health Plan
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 13 Less Insurance Carriers -

Locations

UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER AT DALLAS
5323 Harry Hines Blvd, Dallas, TX 75390
Other Locations
UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER AT DALLAS
6201 Harry Hines Blvd, Dermatology, Dallas, TX 75390
UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER AT DALLAS
6202 Harry Hines Blvd, Dallas, TX 75235
UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER AT DALLAS
2201 Inwood Rd, Dallas, TX 75235

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

Prospective Evaluation of a Standardized Approach to Diagnosis (PREDICT) and Treatment (PATIENCE) of Nontuberculous Mycobacteria Disease in Cystic Fibrosis
Prospective Evaluation of a Standardized Approach to Diagnosis (PREDICT) and Treatment (PATIENCE) of Nontuberculous Mycobacteria Disease in Cystic Fibrosis
Enrollment Status: Enrolling_by_invitation
Publish Date: April 02, 2024
Prospective Evaluation of a Standardized Approach to Diagnosis (PREDICT) and Treatment (PATIENCE) of Nontuberculous Mycobacteria Disease in Cystic Fibrosis
Prospective Evaluation of a Standardized Approach to Diagnosis (PREDICT) and Treatment (PATIENCE) of Nontuberculous Mycobacteria Disease in Cystic Fibrosis
Enrollment Status: Enrolling_by_invitation
Publish Date: April 02, 2024
A Phase 1b/2a, Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety and Tolerability of AP-PA02 Multi-Phage Therapeutic Candidate for Inhalation in Subjects With Cystic Fibrosis and Chronic Pulmonary Pseudomonas Aeruginosa (Pa) Infection
A Phase 1b/2a, Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety and Tolerability of AP-PA02 Multi-Phage Therapeutic Candidate for Inhalation in Subjects With Cystic Fibrosis and Chronic Pulmonary Pseudomonas Aeruginosa (Pa) Infection
Enrollment Status: Completed
Publish Date: January 31, 2024
Intervention Type: Other, Biological
Study Drug: AP-PA02 Bacteriophage
Study Phase: Phase 1/Phase 2
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial to Evaluate Efficacy and Safety of Lenabasum in Cystic Fibrosis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial to Evaluate Efficacy and Safety of Lenabasum in Cystic Fibrosis
Enrollment Status: Completed
Publish Date: January 18, 2023
Intervention Type: Drug, Other
Study Drug: Lenabasum
Study Phase: Phase 2
An Open-label, Non-controlled, Multicenter, Pilot Trial, Using Inhaled Molgramostim in Cystic Fibrosis Subjects With Nontuberculous Mycobacterial (NTM) Infection
An Open-label, Non-controlled, Multicenter, Pilot Trial, Using Inhaled Molgramostim in Cystic Fibrosis Subjects With Nontuberculous Mycobacterial (NTM) Infection
Enrollment Status: Terminated
Publish Date: January 10, 2023
Intervention Type: Device, Drug
Study Phase: Phase 2
Gender Disparity and Hormones in Cystic Fibrosis
Gender Disparity and Hormones in Cystic Fibrosis
Enrollment Status: Completed
Publish Date: August 31, 2020
Intervention Type: Drug
Study Phase: Early Phase 1
Phase 1b, Randomized, Double-blind, Placebo-controlled, Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of QR-010 in Subjects With Homozygous ΔF508 Cystic Fibrosis
Phase 1b, Randomized, Double-blind, Placebo-controlled, Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of QR-010 in Subjects With Homozygous ΔF508 Cystic Fibrosis
Enrollment Status: Completed
Publish Date: February 06, 2019
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
View 6 Less Clinical Trials

105 Total Publications

The Clinical, Psychosocial and Economic Burden of Cystic Fibrosis Lung Disease in the Era of CFTR Modulator Therapy.
The Clinical, Psychosocial and Economic Burden of Cystic Fibrosis Lung Disease in the Era of CFTR Modulator Therapy.
Journal: Annals of the American Thoracic Society
Published: September 17, 2025
Similar Doctors
Experienced in Pseudomonas Stutzeri Infections
Dr. David Maldonado
Pulmonary Medicine | Palliative Medicine | Sleep Medicine
Experienced in Pseudomonas Stutzeri Infections
Dr. David Maldonado
Pulmonary Medicine | Palliative Medicine | Sleep Medicine

David Maldonado Iii MD PA

4401 Booth Calloway Rd, 
North Richland Hills, TX 
 (21.7 miles away)
817-263-6116
Languages Spoken:
English
See accepted insurances
Accepting New Patients

David Maldonado is a Pulmonary Medicine specialist and a Palliative Medicine provider in North Richland Hills, Texas. Dr. Maldonado is rated as an Advanced provider by MediFind in the treatment of Pseudomonas Stutzeri Infections. His top areas of expertise are Parapneumonic Pleural Effusion, Chronic Obstructive Pulmonary Disease (COPD), Lung Metastases, and Pneumonia. Dr. Maldonado is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Jain's expertise for a condition
ConditionClose
View All 8 Advanced Conditions
View All 14 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile